Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDIO NASDAQ:LGVN NYSE:NKGN NASDAQ:PASG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDIOCardio Diagnostics$4.30-6.9%$4.14$3.22▼$53.10$8.03M2.9697,194 shs47,182 shsLGVNLongeveron$1.52-1.3%$1.33$1.14▼$4.29$22.99M0.21586,036 shs322,151 shsNKGNNKGen Biotech$0.24-4.0%$0.29$0.10▼$1.36$10.79M1.261.43 million shs26,099 shsPASGPassage Bio$5.56-3.6%$7.55$5.14▼$26.60$18M1.6721,634 shs85,521 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDIOCardio Diagnostics+0.43%+7.69%+24.19%-60.50%-71.79%LGVNLongeveron+5.48%+2.67%+26.23%+5.48%-60.51%NKGNNKGen Biotech-3.85%-16.67%-13.04%+96.08%-73.29%PASGPassage Bio+3.78%-27.42%-24.18%-12.58%-69.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDIOCardio Diagnostics3.3475 of 5 stars3.55.00.00.02.71.70.6LGVNLongeveron3.3685 of 5 stars3.64.00.00.03.41.70.6NKGNNKGen Biotech0.2653 of 5 stars0.03.00.00.00.02.50.0PASGPassage Bio2.5741 of 5 stars3.52.00.00.01.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDIOCardio Diagnostics 3.00Buy$60.001,295.35% UpsideLGVNLongeveron 3.25Buy$8.67470.18% UpsideNKGNNKGen Biotech 0.00N/AN/AN/APASGPassage Bio 3.00Buy$150.002,597.84% UpsideCurrent Analyst Ratings BreakdownLatest NKGN, LGVN, CDIO, and PASG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDIOCardio Diagnostics$40K187.05N/AN/A$7.10 per share0.61LGVNLongeveron$2.39M9.50N/AN/A$1.47 per share1.03NKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/APASGPassage BioN/AN/AN/AN/A$19.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-28,539.39%-84.55%-74.63%8/11/2025 (Estimated)LGVNLongeveron-$15.97M-$6.280.00N/AN/A-760.72%-85.07%-70.74%8/13/2025 (Estimated)NKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/APASGPassage Bio-$64.77M-$20.40N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)Latest NKGN, LGVN, CDIO, and PASG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PASGPassage Bio-$0.20N/AN/AN/AN/AN/A8/13/2025Q2 2025LGVNLongeveron-$0.35N/AN/AN/A$0.41 millionN/A8/11/2025N/ACDIOCardio Diagnostics-$1.80N/AN/AN/A$0.08 millionN/A5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 million5/13/2025Q1 2025PASGPassage Bio-$4.80-$5.00-$0.20-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDIOCardio DiagnosticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDIOCardio DiagnosticsN/A19.4719.47LGVNLongeveronN/A5.615.61NKGNNKGen BiotechN/A0.020.02PASGPassage BioN/A3.743.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDIOCardio Diagnostics8.06%LGVNLongeveron10.01%NKGNNKGen Biotech76.17%PASGPassage Bio53.48%Insider OwnershipCompanyInsider OwnershipCDIOCardio Diagnostics22.30%LGVNLongeveron11.20%NKGNNKGen Biotech10.36%PASGPassage Bio5.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableLGVNLongeveron2014.93 million13.26 millionNot OptionableNKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionablePASGPassage Bio1303.12 million2.96 millionOptionableNKGN, LGVN, CDIO, and PASG HeadlinesRecent News About These CompaniesPassage Bio Announces 1-for-20 Reverse Stock SplitJuly 10, 2025 | globenewswire.comPassage Bio, Inc. (PASG) Income Statement - Yahoo FinanceJuly 1, 2025 | finance.yahoo.comPASG Passage Bio, Inc. - Seeking AlphaJune 27, 2025 | seekingalpha.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 SharesJune 27, 2025 | insidertrades.comPassage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program UpdateJune 23, 2025 | globenewswire.comPassage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy DevelopmentMay 17, 2025 | msn.comPassage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestreMay 13, 2025 | zonebourse.comZPASSAGE BIO, INC. : Wedbush persiste à l'achatMay 13, 2025 | zonebourse.comZPassage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business HighlightsMay 13, 2025 | globenewswire.comInsider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of StockApril 25, 2025 | insidertrades.comPassage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 SharesApril 18, 2025 | insidertrades.comOrbiMed Advisors vend des actions de Passage Bio pour 49.704$April 18, 2025 | fr.investing.comL’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marchéApril 8, 2025 | fr.investing.comL’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$March 31, 2025 | fr.investing.comL'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$March 14, 2025 | fr.investing.comPassage Bio (PASG) Upgraded to Buy: Here's What You Should KnowMarch 7, 2025 | zacks.comPASSAGE BIO, INC. : Chardan Research reste à l'achatMarch 5, 2025 | zonebourse.comZL’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$March 5, 2025 | fr.investing.comPassage Bio price target lowered to $6 from $7 at ChardanMarch 5, 2025 | markets.businessinsider.comPassage Bio publie ses résultats du quatrième trimestre et de l'année 2024.March 4, 2025 | zonebourse.comZNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNKGN, LGVN, CDIO, and PASG Company DescriptionsCardio Diagnostics NASDAQ:CDIO$4.30 -0.32 (-6.93%) Closing price 04:00 PM EasternExtended Trading$4.22 -0.09 (-1.98%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Longeveron NASDAQ:LGVN$1.52 -0.02 (-1.30%) Closing price 04:00 PM EasternExtended Trading$1.53 +0.01 (+0.66%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.NKGen Biotech NYSE:NKGN$0.24 -0.01 (-4.00%) As of 03:30 PM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Passage Bio NASDAQ:PASG$5.56 -0.21 (-3.64%) Closing price 04:00 PM EasternExtended Trading$5.74 +0.18 (+3.24%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
